Introduction {#Sec1}
============

Lung cancer is currently the most common type of malignant tumor worldwide and the leading cause of death from malignancies \[[@CR1]\]. The incidence of venous thromboembolism (VTE) among ambulatory patients treated for lung cancer can reach 14% \[[@CR2]\]. In addition, chemotherapeutic agents routinely administered for lung cancer therapy also influence the risk of VTE development \[[@CR3], [@CR4]\]. The benefits of routine primary thromboprophylaxis in ambulatory patients receiving chemotherapy for lung cancer have not been clearly demonstrated, and it is currently not recommended \[[@CR5]--[@CR8]\]. However, attempts are being made to identify patients at a high risk of VTE development, who could benefit from primary pharmacological thromboprophylaxis. Recently, a number of risk assessment models (RAMs) predicting the risk of VTE development in patients with solid tumors have been proposed, but their clinical effectiveness in particular tumors remains a matter of debate.

The best-validated model is the Khorana risk score (KRS), in which lung cancer is considered to constitute a high risk of VTE development the KRS \[[@CR9]\]. Other RAMs, the PROTECHT score (PROphylaxis of ThromboEmbolism during CHemoTherapy) and the CONKO score are modifications of the KRS and have not been validated in a homogenous group of patients with lung cancer \[[@CR10], [@CR11]\]. The recently developed COMPASS-cancer-associated thrombosis (COMPASS-CAT) model seems to be most predictive of the risk of VTE development because it includes patient- and cancer-related risk factors, and comorbidities as well as the oncological treatment administered \[[@CR12]\]. Recent studies generally undermine the effectiveness of the KRS in the prediction of VTE in lung cancer \[[@CR13], [@CR14]\]. Moreover, there have been no external validation studies to evaluate the COMPASS-CAT model in clinical practice. To our knowledge, the clinical usefulness of the aforementioned VTE--RAMs has not been directly compared in a group of patients with lung cancer. Therefore, the aim of our study was to validate the KRS, CONKO, PROTECHT and COMPASS-CAT models in a homogenous group of patients treated for lung cancer.

Patients and methods {#Sec2}
====================

Retrospective analysis was performed on newly diagnosed patients with lung cancer who were receiving treatment at the outpatient clinic of the Department of Pulmonology, Allergology and Pulmonary Oncology at Poznan University of Medical Sciences between January 2016 and December 2016. The observation time was defined by the study end date (December 2017), disease progression and occurrence of VTE or death. The data on all-cause mortality between the first of January 2016 and the 31st of December 2017 were based on the reports of the Polish National Health Fund. Patients' data, including complete blood counts, common comorbidities and VTE episodes, were derived from medical records available from the patient's files. Demographic data and clinical cancer details including histopathological diagnosis, stage of disease according to the 7th edition of TNM classification and applied treatment (chemotherapy, radiotherapy, surgery and implementation of central venous catheter) were all analyzed \[[@CR15]\]. Stages IIIB and IV according to TNM (7th edition) were considered advanced disease \[[@CR15]\]. Different chemotherapy schedules were applied, but for our analyses platinum- or gemcitabine-based regimens were taken. None of the patients received anthracyclines-based chemotherapy. Erythropoiesis-stimulating agents were not administered.

Data on the incidence of common comorbidities including coronary artery disease, heart failure, hyperlipidemia, hypertension, atrial fibrillation (paroxysmal/persistent or permanent), stroke, diabetes, chronic obstructive pulmonary disease (COPD), asthma, chronic kidney disease and obesity were obtained. All comorbidities were diagnosed according to the most current guidelines of the relevant international societies and the appropriate treatment recorded in the documentation confirmed the diagnosis of specific diseases. The Charlson comorbidity index (CCI) and simplified comorbidity score (SCS) were also evaluated \[[@CR16], [@CR17]\]. The data on the use of prophylactic aspirin, clopidogrel, vitamin K antagonists (VKA) and DOACs (direct oral anticoagulants) were also collected. Additionally, any history of other malignancies, personal history of VTE and recent hospitalizations for acute medical illness within 3 months before starting treatment were also analyzed.

No routine screening for VTE was performed. The occurrence of VTE was defined as an episode of symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) which appeared after the diagnosis of lung cancer and was confirmed by imaging tests (computed tomography angiography to detect PE or Color and Doppler ultrasound to diagnose DVT). No primary prophylaxis of VTE was administered except for the patients with atrial fibrillation (persistent/recurrent or permanent AF, *n* = 13) including low molecular weight heparin (LMWH, *n* = 8), vitamin K antagonists (VKA, *n* = 4) and 1 patient---rivaroxaban. Among the patients with AF, 83% had a CHA2DS2-VASc risk stratification score ≥ 2 and one patient had a HAS-BLED bleeding risk score above 3 \[[@CR18], [@CR19]\].

For the VTE- risk assessment models estimation, we classified and evaluated the studied lung cancer patients into different risk groups of VTE development according to the following VTE-risk assessment tools: the KRS, the PROTECHT score, the CONKO score and the COMPASS-CAT score \[[@CR9]--[@CR12]\]. According to the KRS, patients were categorized into high-risk (≥ 3 points) group based on the site of cancer (1 point for lung cancer), pre-chemotherapy platelet count over 350 × 10^9^/L, leukocyte count over 11 × 10^9^/L, hemoglobin below 10 g/dl and/or use of erythropoiesis-stimulating agents and a body mass index above 35 kg/m^2^ (BMI, 1 point each) \[[@CR9]\]. The PROTECHT score is the KRS modified by adding platinum or gemcitabine-based chemotherapy (1 point each) to the predictive variables in the KRS, and a score of ≥ 3 points indicates the high-risk group for the development of VTE \[[@CR10]\]. The CONKO score is also a modified KRS in which the BMI is replaced by the Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status ≥ 2 (1 point), and patients with ≥ 3 points are considered as high risk for the development of VTE \[[@CR11]\]. Another model implemented was the COMPASS-CAT model which includes cancer-related risk factors such as anthracycline treatment (6 points), time since cancer diagnosis ≤ 6 months (4 points), central venous catheter (3 points) and advanced stage of cancer (2 points); predisposing risk factors including cardiovascular risk factors (composed of at least two of the following predictors: personal history of peripheral artery disease, ischemic stroke, coronary artery disease, hypertension, hyperlipidemia, diabetes, obesity---5 points), recent hospitalization for acute medical illness (5 points) and personal history of VTE (1 point); biomarkers consisted of platelets count ≥ 350 × 10^9^/L (2 points) \[[@CR12]\]. In the COMPASS-CAT model, high risk for VTE development is assigned to a score of 7 or more points. For the KRS and COMPASS-CAT models, a pre-chemotherapy full blood count was performed by standard methods.

Because our study involved retrospective analysis of existing data with no patient intervention or interaction, and the patient data were de-identified, the Bioethics Committee of Poznan University of Medical Sciences determined that this study was not a medical experiment and was exempt from the Bioethics Committee of Poznan University of Medical Sciences review (No 210/18). Therefore, no consent for participation was required for this study.

Statistical analysis {#Sec3}
--------------------

Based on data from literature \[[@CR20], [@CR21]\], a VTE event rate of about 14% was assumed and it was calculated that at least 115 patients would be required to determine the role of RAMs with a power of 90% using a two-side test at an alpha level of 0.05 when the population size is less than 10,000.
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                \begin{document}$$\bar{x}$$\end{document}$) and standard deviation (SD), are presented for normally distributed variables. Otherwise, medians and the standard errors (SE) with interquartile ranges (25 and 75 percentiles) were used. The Shapiro--Wilk test was performed to assess normality. To compare differences between the groups, the Chi-square test was used for categorical variables and the Mann--Whitney *U* test was used for continuous variables.

Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff values for the VTE-risk assessment models (RAMs) predictive level of VTE development and for the evaluation of the VTE--RAM.s For all VTE--RAMs, we calculated the sensitivity (probability of high risk in those patients experiencing VTE), specificity (probability of high risk in those not experiencing VTE), positive predictive value (PPV, probability of high risk in those patients identified to be at high risk) and negative predictive value (NPV, probability of no VTE in those patients identified to be at low risk) for VTE development.

Univariate logistic regression was used to evaluate potential risk factors that may influence VTE. A multivariate analysis was performed with selected variables that were significant in the univariate analysis (*P *\< 0.01). In each model, the odds ratio (OR) for each independent variable was determined with a confidence interval (CI) of 95%.

The probabilities of survival were estimated via the Kaplan--Meier method, and univariate comparisons were performed via the log-rank test. A *P* value \< 0.05 was regarded as statistically significant. The statistical analyses were performed with STATISTICA 13 and STATISTICA Medical Package (StatSoft, Inc., Tulsa, Oklahoma, USA).

Results {#Sec4}
=======

A total of 118 adult patients with newly diagnosed lung cancer including non-small-cell carcinoma (NSCLC, *n* = 97) or small-cell carcinoma (SCLC, *n* = 21) undergoing chemotherapy were enrolled in the study. All patients were Caucasian, with a median age of 64 years (range 39--83 years), and 58% were male. The median observation time was 14 months (range 1--24). Detailed data concerning the baseline characteristics of the studied population and comparisons of the patients with or without VTE are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the studied population and comparisons of the patients with or without VTECharacteristics*n* (%)VTE^a^ *n* = 20Non-VTE^a^ *n* = 98*P* value*Demographic data*Median age, range years64 (39--83)65 (39--79)63 (46--83)0.3993Gender, male *n* (%)68 (58%)12 (60%)56 (57%)0.8137WHO performance status ≥ 218 (15%)4 (20%)14 (14%)0.5172BMI ≥ 35 kg/m^2^6 (0.05%)1 (5%)5 (5%)0.9849*Comorbidity variables*Coronary artery disease32 (27%)8 (40%)24 (24%)0.1551Heart failure5 (0.04%)0 (0%)5 (5%)0.3019Hyperlipidemia54 (46%)10 (50%)44 (45%)0.6764Hypertension71 (60%)9 (45%)62 (63%)0.1284Atrial fibrillation13 (11%)7 (35%)6 (6%)0.0002Stroke2 (0.02%)1 (5%)1 (15)0.2089Diabetes24 (20%)5 (25%)19 (19%)0.5699COPD25 (21%)5 (25%)20 (20%)0.6469Asthma6 (0.05%)1 (5%)5 (5%)0.9849Chronic kidney disease15 (13%)6 (30%)9 (9%)0.0109Obesity (BMI ≥ 35 kg/m^2^)6 (0.05%)1 (5%)5 (5%)0.9849Presence of comorbidities102 (86%)17 (85%)85 (87%)0.8364High CCI score (≥ 3 points)47 (40%)9 (45%)38 (39%)0.6043High SCS score (score \> 9)30 (25%)7 (35%)23 (23%)0.2805History of other malignancies24 (20%)3 (15%)21 (21%)0.5151Personal history of VTE5 (0.04%)2 (10%)3 (3%)0.1604Recent hospitalization for acute medical illness66 (56%)20 (100%)46 (47%)\< 0.0001Antiplatelet agents (Aspirin)27 (23%)5 (25%)22 (22%)0.8045Anticoagulants13 (11%)7 (35%)6 (6%)0.0017*Histological type*Squamous cell carcinoma37 (31%)5 (25%)32 (33%)0.5016Adenocarcinoma57 (48%)13 (65%)44 (45%)0.1011Small-cell carcinoma21 (18%)2 (10%)19 (19%)0.3171Adenoid cystic adenoma1 (0.01%)0 (0%)1 (1%)--NOS lung carcinoma2 (0.02%)0 (0%)2 (2%)--*Lung cancer-stage according TNM 7th edition*Stage Ia1 (0.01%)0 (0%)1 (1%)--Stage Ib4 (0.03%)0 (0%)4 (4.1%)--Stage IIa4 (0.03%)0 (0%)4 (4.1%)--Stage IIb6 (0.05%)1 (5%)5 (5.2%)--Stage IIIa16 (14%)0 (0%)16 (16.3%)--Stage IIIb15 (13%)3 (15%)12 (12.2%)0.7356Stage IV72 (61%)16 (80%)56 (57.1%)0.0561Advanced disease^b^76 (64%)14 (70%)62 (63%)0.5665*Treatment variables*Surgery5 (4%)0 (0%)5 (5%)--Radiation6 (5%)1 (5%)5 (5%)--Chemotherapy alone39 (33%)8 (40%)31 (32%)0.4683Complex treatment (chemotherapy with surgery or radiation)68 (58%)11 (55%)57 (58%)0.7944Gemcitabine-based chemotherapy25 (21%)9 (45%)16 (16%)0.0042Platinum-based chemotherapy96 (81%)14 (70%)82 (84%)0.1525Central venous catheter7 (6%)1 (5%)6 (6%)0.8465*Pre-chemotherapy CBC variables*Platelet count \> 350 × 10^9^/l40 (34%)6 (30%)34 (35%)0.6861Leukocyte count \> 11 × 10^9^/l26 (20%)4 (20%)22 (22%)0.8097Hemoglobin \< 10 g/dl × 10^9^/l4 (10%)2 (10%)2 (2%)0.0731*Outcome variables*Death76 (64%)16 (80%)60 (61%)0.1100^a^The percentages are related to the numbers presented in the first column of the same line^b^Advanced disease: stage ≥ III B according to the 7th edition of TNM classification*CBC* complete blood count; *CCS* Charlson comorbidity index; *SCS* simplified comorbidity Score*P* \< 0.05---statistically significant

Overall, 20 (16.9%) patients developed venous thromboembolism in the median 2.5 months (25th--75th percentile: 1--7.5), of whom 7 were presented with symptomatic pulmonary embolism, 7 cases were with deep vein thrombosis of lower extremities and 6 patients had both pulmonary embolism and deep vein thrombosis of lower extremities. No impact of the central venous catheter implementation on VTE development was found (1 vs. 5, *p* = 0.8465). Patients with a history of paroxysmal/persistent or permanent AF developed VTE more often than other patients (35 vs. 6%, *P *= 0.0002). Despite the fact that all patients with AF received anticoagulation or thromboprophylaxis with LMWH, 7 out of 13 patients developed VTE including 5 patients on LMWH, 1 patient on VKA and 1 case on rivaroxaban. In comparison with the patients without AF, those with AF less often had heart failure (2 vs. 11, *P *= 0.034). There were no significant differences in other analyzed variables between the patients with or without AF. Comparison of patients with or without VTE demonstrated that patients with chronic kidney disease (CKD) had VTE events more often than patients without CKD (30 vs. 9%, *P *= 0.0109). Furthermore, patients with VTE had more often been hospitalized for acute medical illness within 3 months before starting chemotherapy than the patients without VTE (100 vs. 47%, *P* \< 0.0001). In our study, 80% of patients received platinum-based chemotherapy and 21% of patients had gemcitabine-based regimen. None of the patients received both gemcitabine and platinum at the same time. Furthermore, patients receiving the gemcitabine-based regimen (25%) had a higher incidence of VTE than the patients undergoing other treatment (45 vs. 16%, *P *= 0.0042). No further differences were found between patients with or without gemcitabine-based chemotherapy. There were no significant differences in other patient- and cancer-related risk factors, presence of comorbidities or studied comorbidity scores between the VTE and non-VTE group (Table [1](#Tab1){ref-type="table"}).

VTE occurred in 13% (*n* = 2) of the high-risk group (*n* = 15) and in 17.5% (*n* = 18) of the intermediate group (*n* = 103) according to the KRS, in 17.7% (*n* = 11) of the high-risk group (*n* = 62) and in 16% (*n* = 9) of the low group (*n* = 56) according to the PROTECHT, in 15% (*n* = 4) of the high-risk group (*n* = 26) and in 17.4% (*n* = 16) of the low group (*n* = 92) according to the CONKO and in 23.8% (*n* = 20) of the high-risk group (*n* = 84) and in 0% of the low group (*n* = 34) according to the COMPASS-CAT VTE--RAM. Only the COMPASS-CAT score was able to identify 100% of patients who developed VTE out of the high-risk group (*n* = 84). Detailed comparisons of the patients with or without VTE according to risk assessment models for VTE development are provided in Table [2](#Tab2){ref-type="table"}. Table 2Comparison of the characteristics of patients with and without VTE according to risk assessment models for VTE developmentOverall population *n* = 118VTE group during follow-up^a^ *n* = 20Non-VTE group during follow-up^a^ *n* = 98High KRS^b^15 (13%)2 (10%)13 (13%)High PROTECHT^c^62 (52%)11 (55%)51 (52%)High CONKO^d^26 (22%)4 (20%)22 (22%)High COMPASS^e^84 (71%)20 (100%)64 (65%)^a^The percentages are related to the numbers presented in the first column of the same line^b^According to the Khorana risk score (KRS) for VTE-risk assessment model (VTE--RAM)^c^According to the PROTECHT score for VTE--RAM^d^According to the CONKO score for VTE--RAM^e^According to the COMPASS-CAT score for VTE-RAM*P *\< 0.05: statistically significant

For a high KRS score, the sensitivity was 10%, the specificity 100%, the PPV 17% and the NPV 83%. For a high PROTECH score, the sensitivity was 20%, the specificity 78%, the PPV 18% and the NPV 84%. For a high CONKO score, the sensitivity was 55%, the specificity 48%, the PPV 15% and the NPV 82%. For a high COMPASS-CAT score, the sensitivity was 100%, the specificity 35%, the PPV 24% and the NPV 100%. In our patients treated for lung cancer, the COMPASS-CAT score best discriminated between patients with high and low risk of VTE development (C statistic 0.89). VTE rates and negative and positive predictive values for the development of VTE based on the VTE-RAMs are presented in Table [3](#Tab3){ref-type="table"}. The ROC analysis indicated a cutoff value of 11 points (95% CI 0.821--0.962) for COMPASS-CAT RAM with 95% sensitivity and 61% specificity (ROC AUC = 0.891, SE = 0.036) for the development of VTE, Fig. [1](#Fig1){ref-type="fig"}.Table 3VTE rates and negative and positive predictive values for the development of VTE based on the VTE-risk assessment models in lung cancer patientsRisk groupPatients, *n*VTE, *n*PPV, %NPV, %Sensitivity, %Specificity, %C statistic*KRS score*Low/intermediate10318130100870.81High152178310100*PROTECHT score*Low/intermediate56917010000.51High621118845548*CONKO scoreLow/intermediate*921617010000.49*High*26415822078*COMPASS-CAT score*Low3645317010000.89High64112410010035*PPV* positive predictive value; *NPP* negative predictive value; *VTE* venous thromboembolism Fig. 1Receiver operating characteristic (ROC) curve analysis of COMPASS-CAT RAM for the prediction of VTE development in lung cancer patients

Factors associated with VTE and overall survival {#Sec5}
------------------------------------------------

A high COMPASS-CAT score, gemcitabine chemotherapy, atrial fibrillation, recent hospitalization for acute medical illness and chronic kidney disease were significantly associated with an increased risk of VTE based on the univariate analysis (Table [4](#Tab4){ref-type="table"}). In univariate analysis, there was a trend toward an increased risk of VTE in patients with advanced disease and a pre-chemotherapy hemoglobin value \< 10 g/dl. When variables were included in the multivariate analysis, high COMPASS-CAT score (OR 8.73; 95% CI 1.01--75.22, *P *= 0.049), gemcitabine chemotherapy (OR 3.37; 95% CI 1.09--10.39, *P *= 0.035) and atrial fibrillation (OR 7.19; 95% CI 1.89--27.33, *P *= 0.004) remained significant for VTE development (Table [5](#Tab5){ref-type="table"}).Table 4Univariate analyses of determining factors that affect VTE development in patients with lung cancerFactorOdds ratio (95% CI)*P*High COMPASS-CAT score9.65 (1.24--75.24)0.031Gemcitabine chemotherapy4.12 (1.09--10.39)0.006Atrial fibrillation8.26 (2.40--28.41)0.001Recent hospitalization for acute medical illness0.02 (0.01--0.14)0.001Chronic kidney disease4.24 (1.31--13.75)0.017Advanced disease0.91 (0.29--2.84)0.868 Table 5Multivariate analyses of determining factors that affect VTE development in patients with lung cancerFactorOdds ratio (95% CI)*P*High COMPASS-CAT score8.73 (1.01--75.22)0.049Gemcitabine-based chemotherapy3.37 (1.09--10.39)0.035Atrial fibrillation7.19 (1.89--27.33)0.004

During a median follow-up of 14 months (25th--75th percentile: 7--24 months), 76 patients (64%) died, including 16 patients from the group with VTE and 60 patients from the group without VTE. The median observation time in the group of patients who developed VTE was 14 months (25th--75th percentile: 8--22), in the non-VTE group it was 14 months (25th--75th percentile: 7--24). Although patients with a high Simplified comorbidity score (SCS \> 9) had an increased risk of death (25 vs. 5, *P *= 0.0122), no impact of SCS and CCI on VTE development was found, Table [1](#Tab1){ref-type="table"}.

Discussion {#Sec6}
==========

Herein, we present a study comparing VTE-RAMs in a homogenous group of patients with lung cancer undergoing ambulatory chemotherapy. We demonstrated that with the use of the COMPASS-CAT score we could predict VTE in this group of patients with almost 100% accuracy. To our knowledge, despite the recent debates regarding the risk factors and methods of risk assessment for VTE in various cancers, this is the first such analysis with regard to lung cancer.

Patients with lung cancer are known to have a substantial risk of VTE development. The reported frequency of VTE in outpatient lung cancer patients varies from 5 to 14% \[[@CR2], [@CR13], [@CR20]--[@CR22]\]. VTE in patients with lung cancer results in increased mortality, higher treatment costs and lower quality of life \[[@CR21], [@CR23], [@CR24]\]. To date, routine primary thromboprophylaxis in ambulatory patients with lung cancer has not been recommended \[[@CR5]--[@CR8]\]. Several attempts have been made to examine the effectiveness of primary thromboprophylaxis in patients with lung cancer. The FRAGMATIC study revealed a significantly lower rate of VTE in patients receiving dalteparin, but without an impact on overall prognosis and a higher incidence of bleeding \[[@CR25]\]. Ek et al. \[[@CR26]\] in a RASTEN trial including patients with SCLC showed similar results. Most of the studies conclude that the benefit from primary thromboprophylaxis should be weighed against the risk of bleeding \[[@CR27]\]. In order to identify those patients at a particularly high risk of VTE who could benefit from primary thromboprophylaxis, several RAMs have been proposed, based on heterogeneous groups of patients with common tumors. Most of these RAMs have not yet been validated with a group of patients with lung cancer.

The KRS was originally derived from a cohort of outpatients with common malignancies (patients with lung cancer accounted for 20% of the group), undergoing chemotherapy, with a median observation time of 2.5 months. In the original cohort, it appeared to be predictive of VTE \[[@CR9]\]; however, subsequent studies did not confirm the efficacy of KRS in the prediction of VTE in cancer patients \[[@CR13], [@CR28], [@CR29]\]. Moreover, previous attempts to validate the KRS in patients with lung cancer did not confirm its efficacy in this particular malignancy \[[@CR14]\], which is in line with our results. In the present study, KRS also failed in risk stratification for VTE.

The PROTECHT score is a modification of the KRS including chemotherapy agents related to high risk of VTE (platinum, gemcitabine) \[[@CR10]\]. These agents are routinely used in treatment of advanced lung cancer and both agents increase the risk of VTE \[[@CR3], [@CR4], [@CR30]\], particularly when administered together \[[@CR31]\]. In the studied group, none of the patients received both agents in a combined chemotherapy regimen, although in some patients they were administered consecutively. However, despite the widespread use of these chemotherapeutics in the study group there was no correlation between the PROTECHT score and incidence of VTE. In line with the findings of Barni et al. \[[@CR32]\], the presented study demonstrated an increased incidence of VTE in patients receiving gemcitabine when compared to other agents. In our study, a gemcitabine-based regimen was associated with approximately 3.0-fold increase odds for VTE occurrence.

The CONKO score, originally validated in ambulatory patients with pancreatic cancer, modifies KRS by replacing BMI with performance status (PS) \[[@CR11]\]. Poor PS has also been found to be predictive of VTE in patients with non-small-cell lung cancer \[[@CR33]\]. Because the studied group in our study comprised patients eligible for ambulatory chemotherapy, the PS according to ECOG classification in the majority of them was 0--1 points. Thus, patients with PS ≥ 2 were underrepresented (*n* = 18) in our study as they were assigned 1 point in the CONKO score, which resulted in the high occurrence of intermediate-risk patients in the study group. This might explain the poorer performance of this score in our study group.

The recently proposed COMPASS-CAT score includes a number of variables related to patient characteristics, comorbidities, tumors and treatment \[[@CR12]\]. In the original cohort, lung cancer patients accounted for 13.3%. A score of 7 points indicated a high risk of VTE \[[@CR12]\]. We found the COMPASS-CAT score proved to be the only discriminative model among the VTE--RAMs analyzed in our study. However, in contrast to the original work, in our group of patients with lung cancer we identified a score of 11 points as a cutoff point indicating a high risk of VTE development. Our result is encouraging and can improve the COMPASS-CAT performance in lung cancer patients. Furthermore, this score is applicable not only at the beginning of the oncologic treatment, but also in patients already receiving chemotherapy, allowing re-assessment of the risk of VTE during treatment.

We also attempted to identify specific patient--related risk factors for VTE, which could be considered independently of the proposed RAMs or indicate clinically important characteristics not included in the RAMs. In the univariate analysis, a recent hospitalization for acute medical illness before starting oncological treatment was a factor related to an increased risk of VTE, independent of the COMPASS-CAT score, which is consistent with previous observations \[[@CR34]\]. However, this finding was not confirmed in multivariate analysis.

Moreover, in the present study the impact of comorbidities on the risk of VTE development was analyzed. The association between CKD and VTE occurrence has previously been demonstrated in the general population \[[@CR35]\], but in cancer patients with CKD the data are contradictory \[[@CR36], [@CR37]\]. In the univariate model, the patients with lung cancer and CKD had an above 4.0-fold increased risk of VTE. As our patients were eligible for ambulatory chemotherapy and had less advanced stages of CKD, the increased risk of VTE related to CKD was not confirmed in the multivariable model which determined factors that may affect VTE development in our patients with lung cancer.

Atrial fibrilation (AF) is known as a factor related with VTE in the general population \[[@CR38]\]. In the presented study, AF was identified in both univariate and multivariate analyses as an independent risk factor for VTE events. Despite anticoagulation therapy (vitamin K antagonists, VKA or non-VKA oral anticoagulants, NOACs) or thromboprophylaxis with LMWH, AF was associated with an approximately 7.0-fold increase in the odds for VTE development. Therefore, atrial fibrillation appears to be an especially strong risk factor of VTE and could be considered in future RAMs tailored for lung cancer.

Currently, there are no specific recommendations for chronic anticoagulation in patients with active cancer and non-valvular atrial fibrillation. As in the general population the assessment of the risk-to-benefit ratio between thrombotic risk (a CHA2DS2-VASc score greater than or equal to 2) and bleeding risk (a HAS-BLED bleeding risk score below 3) should be considered \[[@CR18], [@CR19]\]. VTE occurred despite anticoagulation, which illustrates a strong tendency for the development of VTE in this group of patients. Our observation is in line with previous studies on cancer patients with AF that reports an elevated risk of VTE despite prophylaxis with VKA \[[@CR39]\] or other anticoagulants \[[@CR40]\]. In our study, the limited number of patients with lung cancer and AF on various anticoagulants did not allow for the determination of the optimal therapy, thus making the results inconclusive in this area and require further studies necessary.

In our study the highest incidence of VTE was observed within the first months after the beginning of treatment (median 2.5 months). Recent studies also reported the highest tendency for VTE development in the first few months \[[@CR21], [@CR41]\]. This finding supports the need for pre-chemotherapy assessment of the risk of VTE \[[@CR42]\].

The main strength of the present study is the novel direct comparison of RAMs designed for the prediction of VTE in a representative, homogenous group of patients with lung cancer, treated in a single reference hospital. As the patients received the majority of their treatment on this one site, the collected clinical data were complete and reflected the real incidence of symptomatic VTE in the study group. The main limitation of the study is its retrospective character. Moreover, because there was no routine screening for VTE, some cases of asymptomatic VTE may have been missed.

In conclusion, our study indicated the COMPASS-CAT score as the RAM most effective at predicting VTE in lung cancer, however, only after taking into account the modified high-risk cutoff point. These results underline the need for a RAM tailored especially for patients with lung cancer.
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